RxDoctor Payments Data

Richard Yamamoto, MD

Internal Medicine · Carson City, NVNPI 1215083753

Payments from drug & device makers

$395in general payments, 2019–2025

Across 19 payments — averaging $20.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$92
  • Johnson & Johnson$77
  • Pfizer$71
  • Boehringer Ingelheim$25
  • Abbott$24
  • Merck$23
  • plus $84 from 5 others

What the payments were for

  • Food & beverage$36492%
  • Education$328%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$395 in reported general payments places this provider in the 55th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$159,705
Medicare patients
443
Services billed
1,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide101$114,880
MounjaroTirzepatide70$83,042
JardianceEmpagliflozin55$69,222
EliquisApixaban43$46,094
FarxigaDapagliflozin Propanediol26$22,643
XareltoRivaroxaban14$19,230
MyrbetriqMirabegron20$17,807
JanumetSitagliptin Phos/Metformin Hcl11$17,701
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$13,575
NexletolBempedoic Acid16$11,227
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$9,564
Rosuvastatin Calcium368$7,091
Breo ElliptaFluticasone/Vilanterol12$6,820
SynthroidLevothyroxine Sodium65$6,031
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$5,308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$18$83,04270 claims
Boehringer IngelheimJardiance$25$69,22255 claims
PfizerEliquis$71$46,09443 claims
GSKTrelegy Ellipta, Breo Ellipta$19$20,39525 claims
Johnson & JohnsonXarelto$77$19,23014 claims
MerckJanumet$23$17,70111 claims
Esperion Therapeutics, Inc.Nexletol$15$11,22716 claims
AbbVieSynthroid$92$6,03165 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Carson City

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →